Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Reply to: When PIK3CA Wild-Type Becomes a Biomarker Blind Spot.

Created on 10 Oct 2026

Authors

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, Barbara Pistilli

Published in

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Pages JCO2601653. Oct 09, 2026. Epub Oct 09, 2026.

PMID:
42854111
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement